Cancer reports (Hoboken, N.J.) · 2026
Retrospective Analysis of Zolbetuximab-Associated Hypoalbuminemia in Claudin 18.2-Positive Advanced Gastric Cancer.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mizuno Taro, Narita Yukiya, Ando Taiju, Ishizuka Yasunobu, Umegaki Sho, Honda Kazunori, Masuishi Toshiki, Taniguchi Hiroya, Kadowaki Shigenori, Ando Masashi, Tajika Masahiro, Muro Kei
Аннотация
BACKGROUND: Hypoalbuminemia has been recognized as a characteristic adverse event associated with zolbetuximab plus chemotherapy in the treatment of claudin 18.2-positive advanced gastric cancer. However, its incidence, clinical predictors, and management in real-world settings remain unclear.
AIMS: We aimed to characterize the course of hypoalbuminemia during zolbetuximab-based therapy and identify factors associated with its severity and recovery.
METHODS AND RESULTS: We retrospectively analyzed patients with advanced gastric cancer treated with zolbetuximab plus chemotherapy at a single center, tracking serial serum albumin levels. Severe hypoalbuminemia was defined as a nadir albumin < 2.0 g/dL and/or a ≥ 1.0 g/dL decrease from baseline. Associations between severe hypoalbuminemia and clinicopathological factors were assessed, along with its management strategies. A total of 39 patients were included in the analysis. Hypoalbuminemia occurred in all patients, and 20 (51.3%) developed severe hypoalbuminemia. Prior total gastrectomy was associated with a lower incidence of severe hypoalbuminemia (0% vs. 58.8%, p = 0.02), whereas persistent nausea and/or vomiting beyond the zolbetuximab infusion during the first cycle was associated with a higher risk (63.0% vs. 25.0%, p = 0.04). Recovery of serum albumin levels was observed in 18 patients (46.2%) and occurred more frequently among those who temporarily interrupted zolbetuximab plus chemotherapy or zolbetuximab alone (66.7% vs. 28.6%, p = 0.03).
CONCLUSION: Severe hypoalbuminemia was common in patients receiving zolbetuximab plus chemotherapy in real-world practice. The absence of prior total gastrectomy and the presence of persistent post-infusion nausea and/or vomiting may help identify patients at risk. The observed association between temporary treatment interruption and albumin recovery may provide insights into the management of hypoalbuminemia.
AIMS: We aimed to characterize the course of hypoalbuminemia during zolbetuximab-based therapy and identify factors associated with its severity and recovery.
METHODS AND RESULTS: We retrospectively analyzed patients with advanced gastric cancer treated with zolbetuximab plus chemotherapy at a single center, tracking serial serum albumin levels. Severe hypoalbuminemia was defined as a nadir albumin < 2.0 g/dL and/or a ≥ 1.0 g/dL decrease from baseline. Associations between severe hypoalbuminemia and clinicopathological factors were assessed, along with its management strategies. A total of 39 patients were included in the analysis. Hypoalbuminemia occurred in all patients, and 20 (51.3%) developed severe hypoalbuminemia. Prior total gastrectomy was associated with a lower incidence of severe hypoalbuminemia (0% vs. 58.8%, p = 0.02), whereas persistent nausea and/or vomiting beyond the zolbetuximab infusion during the first cycle was associated with a higher risk (63.0% vs. 25.0%, p = 0.04). Recovery of serum albumin levels was observed in 18 patients (46.2%) and occurred more frequently among those who temporarily interrupted zolbetuximab plus chemotherapy or zolbetuximab alone (66.7% vs. 28.6%, p = 0.03).
CONCLUSION: Severe hypoalbuminemia was common in patients receiving zolbetuximab plus chemotherapy in real-world practice. The absence of prior total gastrectomy and the presence of persistent post-infusion nausea and/or vomiting may help identify patients at risk. The observed association between temporary treatment interruption and albumin recovery may provide insights into the management of hypoalbuminemia.